Phase IIa, Double-Blind, Placebo-Controlled, Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With Polycystic Ovarian Syndrome
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2017
Price : $35 *
At a glance
- Drugs Fezolinetant (Primary)
- Indications Polycystic ovary syndrome
- Focus Therapeutic Use
- Sponsors Ogeda
- 31 Aug 2018 Biomarkers information updated
- 31 Aug 2017 This trial has been completed in Netherland.
- 07 Aug 2017 This trial has been completed in Belgium on (2017-05-01), according to European Clinical Trials Database record.